Roche

News

Roche's TIGIT ambitions take another blow

Roche's anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its cancer immunotherapy blockbuste

News

Roche extends Kaiku digital monitoring partnership again

Roche has elevated a longstanding alliance with Finland's Kaiku Health focusing on digital patient monitoring and management (DPMM) to the level of a strategic partnership.

News

CHMP backs Roche's lymphoma bispecific mosunetuzumab

Roche is on the brink of its first regulatory approval for what could be the first bispecific antibody targeting CD3 and CD20 – mosunetuzumab – after getting a positive opinion for the drug

News

Roche's oral SERD giredestrant fails breast cancer trial

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the eme

Digital

Various connections implying a world map

The largest pharma company in Europe calls for interoperabil...

Ehab Youssef, area head of Europe North at Roche Pharmaceuticals, tells us why European countries need interoperability to ensure a more effective overall European healthcare system.

News

Roche hit by failure of TIGIT drug tiragolumab in lung cance...

Roche has suffered a setback with its much-anticipated pairing of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq in small cell lung cancer (SCLC), in a blow to its ambitions

Roche's TIGIT ambitions take another blow

Roche extends Kaiku digital monitoring partnership again

CHMP backs Roche's lymphoma bispecific mosunetuzumab

Roche's oral SERD giredestrant fails breast cancer trial

The largest pharma company in Europe calls for interoperabil...

Roche hit by failure of TIGIT drug tiragolumab in lung cance...

ADARx, Trex, and Retension take aim at IPOs

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks